Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Use of CRISPR & RNAi for Drug Discovery, CHI’s World PreClinical Congress – Europe, November 14-15, 2016, Lisbon, Portugal

Reporter: Aviva Lev-Ari, PhD, RN

Use of CRISPR & RNAi for Drug Discovery, CHI’s World PreClinical Congress – Europe, November 14-15, 2016, Lisbon, Portugal, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Cambridge Healthtech Institute’s inaugural conference on Use of CRISPR & RNAi for Drug Discovery will cover the latest in the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9-based gene editing and RNA interference (RNAi) for use in drug discovery and for developing novel drug therapies. It will bring together experts from all aspects of basic science and clinical research to talk about how and where gene editing and RNAi can be best applied. The talks will discuss how the CRISPR/Cas system compares to RNAi and if they can be used in a complementary fashion. Scientists and clinicians will share best practices on everything from assay design to data analysis when conducting low and high throughput screens and generating cellular models, both in vitro and in vivo, using CRISPR/Cas9, siRNA (small interfering RNA), and shRNA (short hairpin RNA) for functional screening, pathway analysis, target discovery, disease modeling, and for enabling cell and viral therapies.

Preliminary Agenda

CREATING MODELS AND CELL LINES USING CRISPR/Cas9

Applications of CRISPR/Cas9 for Drug Discovery

Lorenz Mayr, Ph.D., Vice President and Global Head, Biological Reagents & Assay Development, Discovery Sciences, AstraZeneca R&D

Generation of in vivo Preclinical Models with the CRISPR/Cas9 System

Danilo Maddalo, Ph.D., Lab Head, ONC Pharmacology, Novartis Institutes for BioMedical Research, Novartis Pharma AG

FUNCTIONAL SCREENS USING CRISPR & RNAi

Large Scale CRIPSR Screens for Discovery of Genotype Specific Combination Therapies

Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center

GPCR-Mediated cAMP as an Immune Checkpoint in Cancer Identified by RNAi Screening

Tillmann Michels, Head of Research Group, Immune Checkpoint Inhibitors, Department of Interventional Immunology, Regensburg Center for Interventional Immunology; Member, Department of Translational Immunology, German Cancer Research Center

A Loss of Function RNAi Screen to Identify New Pathways and Genes Essential for Nucleolar Stress Response

Kaylene J. Simpson, Ph.D., Associate Professor and Head, Victorian Centre for Functional Genomics ACRF Translational RPPA Platform, Peter MacCallum Cancer Centre, Australia

Pooled CRISPR-Cas9 Screening: A Powerful Functional Genomics Tool for Translating Biological Entities Into Druggable Targets

Ralph Garippa, Ph.D., Director, RNAi & Gene Editing Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

Systematic Comparison of CRISPR/Cas9 and shRNA Screens For the Identification of Drug Targets and Essential Genes

Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University

BUILDING THE CRISPR TOOLBOX

Chemogenomics Using CRISPR – Old Tricks for New Dogs

Dominic Hoepfner, Ph.D., Researcher, Developmental & Molecular Pathways, Novartis Institutes for BioMedical Research, Novartis Pharma AG

MicroRNA Target Site Editing by CRISPR-Cas9 in Primary Human Chondrocytes

Christine Seidl, Ph.D., Post-Doctoral Research Associate, Cell Signaling, Kennedy Institute of Rheumatology, Oxford University

Technology Panel: Trends in CRISPR & RNAi Technologies

This panel will bring together 4-5 technical experts from leading technology and service companies to discuss trends and improvements in library design, assay reagents

For questions or suggestions about the meeting, please contact:

Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com

For sponsorship and exhibit sales information, including sponsored podium presentations, contact:

Companies A-K:
Ilana Quigley
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5457
E: iquigley@healthtech.com

Companies L-Z
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com

SOURCE

http://www.worldpreclinicaleurope.com/CRISPR-and-RNAi-for-Drug-Discovery/